Applied Cognition’s lead candidate, ACX-02—a fixed-dose small molecule combination with an oral formulation under a new chemical entity (NCE) patent application—is designed to enhance three key brain physiologies that regulate glymphatic function during sleep. ACX-02 has demonstrated a significant increase in the clearance of amyloid beta and tau proteins from the brain to the plasma following a single dose. Additional findings support its role in suppressing senescence-associated inflammatory cytokines and chemokines, while also promoting the expression of growth factors.

Through its platform, Applied Cognition has uncovered a link between neurovascular function and astrocyte-mediated neuropil resistance, revealing a novel druggable target in humans. The company plans to further probe this CNS target with its platform.

The Applied Cognition platform enables new target discovery for enhancing glymphatic clearance of toxic proteins in Alzheimer’s disease and related dementias.